.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently developed a novel approach using chloramphenicol transfersome delivery to treat eye infections. Specifically, they focused on applying these formulations directly onto the eyelid skin. Consequently, this method aims to bypass traditional ocular barriers. Furthermore, the study utilized transfersomes with an average size of 120 nm. Because these vesicles are monodispersed, they ensure uniform drug distribution. Moreover, this innovation could revolutionize how we manage bacterial conjunctivitis in clinical settings.
These ultra-deformable vesicles offer several clinical advantages. However, traditional eye drops often wash away quickly. In contrast, transfersomes penetrate the eyelid skin to reach the conjunctiva. Therefore, this system provides a sustained therapeutic effect. Additionally, the non-invasive nature improves patient compliance significantly. Ultimately, clinicians can expect better outcomes with reduced dosing frequency.
The skin of the eyelid acts as a gatekeeper for topical medications. Similarly, the unique composition of transfersomes allows them to squeeze through the stratum corneum. Hence, the drug reaches the infection site without direct irritation to the eyeball. Notably, this method reduces systemic side effects by focusing on local delivery. As a result, it provides a safer alternative for sensitive populations like children.
Transfersomes contain edge activators that make them ultra-deformable. Consequently, they can squeeze through tiny pores in the skin more effectively than rigid liposomes. This enhances drug penetration significantly.
Eyelid application allows the drug to penetrate the skin and reach the conjunctiva locally. Therefore, it reduces the discomfort and rapid drainage issues associated with traditional eye drops. This ensures a higher concentration of the drug stays at the target site.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Grygor'yeva L et al. Chloramphenicol Application Onto the Eyelid: Transfersomes for Enhanced Skin Delivery. AAPS PharmSciTech. 2026 Jun 11. doi: undefined. PMID: 42277546.
Vyavahare SS, et al. Chloramphenicol Overview in Eye Infections. International Journal of Pharmacy & Pharmaceutical Research. 2024; 30(5): 72-84.
Dua A, et al. Transfersomes: A Vesicular Tool for Transdermal Drug Delivery. Innovative Lipid-Based Vesicles. 2026.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers have developed chloramphenicol-loaded transfersomes (120 nm) to treat conjunctivitis via eyelid application. This novel delivery system enhances drug permeability and stability, offering a promising non-invasive alternative to traditional eye drops for managing ocular infections.
last month
Researchers at SGPGIMS Lucknow have isolated and cultured human heart valve interstitial cells from donor tissues. This milestone advances understanding of rheumatic heart disease pathways like TGF-beta/SMAD3 and ERK1/2, laying the foundation for tissue-engineered heart valves and drug testing.
Today
Johnson & Johnson announced a $5.5 billion settlement to resolve nearly 69,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. This comprehensive deal covers 99.75% of active claims. Read about the legal strategy, scientific evidence on talc exposure, and clinical counseling for patients.
Today
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
4 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
4 days back
Deepinder Goyal's healthtech startup Temple is raising capital at a $500 million valuation and pricing its temporal wearable at Rs 80,000. Worn on the side of the forehead, the device tracks microvascular blood flow and real-time Entropy to monitor physiological stress, metabolic expenditure, and recovery.
Today
